close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
A Japanese health ministry panel on Monday recommended approval of the Alzheimer’s disease treatment Leqembi, following standard approval for the drug granted by U.S. regulators last month.
REVANCE’S BOTOX RIVAL GETS FDA APPROVAL FOR PAINFUL NECK MUSCLE CONDITION
The expert panel’s decision sets the stage for official approval of the drug, co-developed by Japan’s Eisai and U.S.-based Biogen.
Dr. Seth Gale points out evidence of Alzheimer’s disease on PET scans at the Center for Alzheimer Research and Treatment (CART) at Brigham and Women’s Hospital in Boston, Massachusetts, on March 30, 2023. (REUTERS/Brian Snyder/File Photo)
An Eisai executive said this month the company expects to begin marketing Leqembi in Japan within about 60 days of receiving insurance reimbursement approval from the country’s national health system.
CLICK HERE TO GET THE FOX NEWS APP
If your smartphone stays on your bedside table overnight, it stays busy long after you…
Artificial Intelligence and data centers have been blamed for rising electricity costs across the U.S.…
The Super Bowl is not only the biggest sporting event of the year, but it…
Since news broke in late January that TikTok's U.S. operations would move under American-led ownership,…
Losing the ability to speak clearly after a stroke can feel devastating. For many survivors,…
Tax season already brings stress. In 2026, it brings added confusion. Changes to tax filing…